Free Trial
NASDAQ:GNLX

Genelux 3/28/2025 Earnings Report

Genelux logo
$2.51 -0.12 (-4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$2.69 +0.18 (+7.33%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Genelux Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genelux Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Genelux's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Genelux Earnings Headlines

Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Genelux reports FY24 EPS (95c), consensus (88c)
Genelux announces alignment with FDA of approval pathway for Olvi-Vec
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX), a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

View Genelux Profile

More Earnings Resources from MarketBeat